We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Gastric Bacterium Associated with Poor Blood Sugar Control

By LabMedica International staff writers
Posted on 28 Mar 2012
Print article
The presence of the bacterium Helicobacter pylori has been linked to higher levels of the diabetes biomarker glycated hemoglobin (HbA1c).

Helicobacter pylori are gram-negative bacteria that colonize the human stomach and HbA1c is a biomarker that reflects integrated blood glucose levels during the preceding 3-4 months in patients with diabetes.

Scientists at New York University School of Medicine (NY, USA) conducted a cross sectional analysis of 7,417 participants from one study and 6,072 participants from another. The HbA1c measurements were performed using the Diamat Analyzer System or the CLC330/CLC 385 analyzer. Participants were tested for H. pylori immunoglobulin G (IgG) antibodies using a H. pylori IgG enzyme-linked immunosorbent assay (ELISA) and for cytotoxic associated protein (cagA) IgG with an in-house ELISA.

Among the overall population, those who were H. pylori–positive had higher mean HbA1c levels. The positive association was more apparent among those aged 18 years or more. In contrast, among those who were younger, there was no association between H. pylori and HbA1c levels. There was a progressive increase in HbA1c when comparing participants who were H. pylori–negative, H. pylori–positive/cagA-negative, and H. pylori–positive/cagA-positive subjects in the overall study population. The study, not only revealed the impact of H. pylori on the diabetes biomarker, but also how overweight and obese patients are affected even more, and will probably change the way future diabetes treatments are decided upon.

The Diamat Analyzer System is manufactured by Bio-Rad Laboratories, (Hercules, CA, USA) and the CLC330/CLC 385 analyzer is a product of Primus (Kansas City, MO, USA). The H. pylori IgG ELISA was obtained from Wampole Laboratories (Wampole Laboratories, Cranbury, NJ, USA). Yu Chen, PhD, MPH, the lead author of the study, said, "If future studies confirm our finding, it may be beneficial for individuals at risk for diabetes to be tested for the presence of H. pylori depending on the individual's risk factor profile." The authors added that perhaps some older diabetes patients might benefit from a course of antibiotics to eradicate the bacterium. The study was published on March 13, 2012, in the Journal of Infectious Diseases.

Related Links:
New York University School of Medicine
Bio-Rad Laboratories
Primus

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.